Insider · SEC Form 4 filer

Erez Chimovits

Companies

Where they file as an insider

ADARx Pharmaceuticals (ADRX) Director Latest filing Sep 28, 2026
Braveheart Bio (BRVE) Director, 10% owner Latest filing Aug 7, 2026
Upstream Bio (UPB) Director, 10% owner Latest filing Oct 15, 2024

Track record

Did their buys beat the typical stock?

Open-market buys5
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check2

Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.

ADARx Pharmaceuticals (ADRX) Bought Sep 28, 2026 · $1.05M · 61,516 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Braveheart Bio (BRVE) Bought Aug 7, 2026 · $34.9M · 1.94M shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Upstream Bio (UPB) Bought Oct 15, 2024 · $14M · 825,000 shares Behind typical Dec 31, 2024 $16.44 → Jun 30, 2025 $10.98 · −33.2% (typical stock −3.4%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist